Statins × cardiovascular events

SynthesisAnnals of internal medicine2012

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Suetonia C Palmer et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 51,099 people · 2012

Not counted

Reduced deaths

−19%−26% to −12%

Bigger than 6 in 10 for all-cause mortality

As reported

RR 0.81, 95% CI 0.74–0.88 · the paper's word: All-cause mortality

Not counted

Reduced cardiovascular events

−22%−32% to −11%

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.78, 95% CI 0.68–0.89

Not counted

Reduced cardiovascular events

−24%−27% to −20%

Bigger than 6 in 10 for cardiovascular events

As reported

RR 0.76, 95% CI 0.73–0.80

Range includes no effect

No clear effect on deaths

−4%−12% to +4%

Bigger than 2 in 10 for all-cause mortality

As reported

RR 0.96, 95% CI 0.88–1.04 · the paper's word: All-cause mortality

+2 more in the walkthrough ↓

Six numbers in the abstract

the abstract, start to end

all-cause mortality (relative risk [RR], 0.81 [95% CI, 0.74 to 0.88]), cardiovascular mortality (RR, 0.78 [CI, 0.68 to 0.89]), and cardiovascular events (RR, 0.76 [CI, 0.73 to 0.80]) in persons

or no effect on all-cause mortality (RR, 0.96 [CI, 0.88 to 1.04]), cardiovascular mortality (RR, 0.94 [CI, 0.82 to 1.07]), or cardiovascular events (RR, 0.95 [CI, 0.87 to 1.03]) in persons

← favours treatmentfavours comparator →
could be chance
All-cause mortality
RR 0.810.74–0.88
Cardiovascular events
RR 0.780.68–0.89
Cardiovascular events
RR 0.760.73–0.80
All-cause mortality
RR 0.960.88–1.04
Cardiovascular events
RR 0.940.82–1.07
Cardiovascular events
RR 0.950.87–1.03
StatinsCardiovascular eventsAll-cause mortality
1 / 3

150 papers cite itlatest 60 shown

2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 22910937